When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ImmunoGen(NASDAQ: IMGN) floundered throughout much of 2019, with the stock down more than 50% year to date by October. But some encouraging news from a late-stage clinical study evaluating mirvetuximab soravtansine renewed investors' enthusiasm soon afterward. ImmunoGen stock soared and kept the momentum going in subsequent months.
The biotech announced its 2019 fourth-quarter and full-year results before the market opened on Friday, fueling the fire even more. Here are the highlights from ImmunoGen's Q4 update.